Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.41 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.41 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235137 | 0.88 | BCL9 (0.56) | BCL9CTNNB1HTR2AGAAMGLL | |
| SCHEMBL2234610 | 0.86 | BCL9 (0.68) | BCL9CTNNB1HTR2AGAAMGLL | |
| SCHEMBL15459741 | 0.85 | HTR2A (0.53) | BCL9CTNNB1HTR2AGAAMGLL | |
| SCHEMBL14453837 | 0.84 | BCL9 (0.65) | BCL9CTNNB1HTR2AGAAMGLL | |
| SCHEMBL2233659 | 0.83 | HTR2A (0.52) | BCL9CTNNB1HTR2AGAAMGLL | |
| SCHEMBL6447049 | 0.83 | BCL9 (0.53) | BCL9CTNNB1HTR2AGAAMGLL | |
| SCHEMBL2235530 | 0.82 | HTR2A (0.54) | BCL9CTNNB1HTR2AGAAMGLL | |
| SCHEMBL7989561 | 0.82 | HTR2A (0.53) | BCL9CTNNB1HTR2AGAAMGLL | |
| SCHEMBL2235180 | 0.81 | BCL9 (0.48) | BCL9CTNNB1HTR2AGAAMGLL | |
| SCHEMBL22364451 | 0.81 | HTR2A (0.46) | BCL9CTNNB1HTR2AGAAMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | BCL9 2611/4885CTNNB1 4803/4885HTR2A 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.